Claims for Patent: 8,445,507
✉ Email this page to a colleague
Summary for Patent: 8,445,507
| Title: | Androgen receptor modulator for the treatment of prostate cancer and androgen receptor-associated diseases |
| Abstract: | A hydantoin compound useful for the prevention or treatment of hyperproliferative diseases or disorders. |
| Inventor(s): | Jung; Michael E. (Los Angeles, CA), Sawyers; Charles L. (New York, NY), Ouk; Samedy (Los Angeles, CA), Tran; Chris (New York, NY), Wongvipat; John (New York, NY) |
| Assignee: | The Regents of the University of California (Oakland, CA) |
| Application Number: | 12/294,881 |
| Patent Litigation and PTAB cases: | See patent lawsuits and PTAB cases for patent 8,445,507 |
| Patent Claims: |
1. A compound having the formula ##STR00025## , or a pharmaceutically acceptable salt thereof.
2. A pharmaceutical composition comprising a therapeutically effective amount of a compound of claim 1, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier, diluent, or adjuvant. 3. A method for treating a hyperproliferative disorder comprising administering a compound of claim 1, or a pharmaceutically acceptable salt thereof, to a subject in need of such treatment, thereby treating the hyperproliferative disorder wherein the hyperproliferative disorder is prostrate cancer. 4. The method of claim 3, wherein the compound or a pharmaceutically acceptable salt thereof, is administered at a dosage in the range of from 0.01 mg per kg body weight per day to 500 mg per kg body weight per day. 5. The method of claim 3, wherein the compound, or a pharmaceutically acceptable salt thereof, is administered at a dosage in the range of from 0.1 mg per kg body weight per day to 200 mg per kg body weight per day. 6. The method of claim 3, wherein the compound or a pharmaceutically acceptable salt thereof, is administered at a dosage in the range of from 1 mg per kg body weight per day to 50 mg per kg body weight per day. 7. The method of claim 3, wherein the compound or a pharmaceutically acceptable salt thereof, is administered at a dosage of 10 mg per kg body weight per day. 8. The method of claim 3, wherein the compound is administered by intravenous injection, by injection into tissue, intraperitoneally, orally, or nasally. 9. The method of claim 3, wherein the compound has a form selected from the group consisting of a solution, dispersion, suspension, powder, capsule, tablet, pill, time release capsule, time release tablet, and time release pill. 10. The pharmaceutical composition of claim 2, wherein the compound is ##STR00026## 11. The pharmaceutical composition of claim 2, wherein the compound is ##STR00027## 12. The pharmaceutical composition of claim 2, comprising a solution of dimethylsulfoxide and phosphate buffered saline solution. 13. The pharmaceutical composition of claim 2, comprising polyethylene glycol. 14. The pharmaceutical composition of claim 2, wherein the compound is at a concentration of 1.5 mg/mL. 15. The pharmaceutical composition of claim 2, comprising a solution of dimethylsulfoxide, a carboxymethylcellulose, a polysorbate, and water. 16. The method of claim 3, wherein the hyperproliferative disorder is hormone sensitive prostate cancer. 17. The method of claim 3, wherein the hyperproliferative disorder is hormone refractory prostate cancer. 18. The method of claim 3, wherein the compound has the formula: ##STR00028## 19. The method of claim 3, wherein the compound has the formula: ##STR00029## 20. The compound of claim 1, wherein the compound has the formula: ##STR00030## 21. The pharmaceutically acceptable salt of a compound of claim 1, wherein the compound has the formula: ##STR00031## 22. The compound of claim 1, wherein the compound has the formula: ##STR00032## 23. The pharmaceutically acceptable salt of a compound of claim 1, wherein the compound has the formula: ##STR00033## 24. A pharmaceutical composition comprising a therapeutically effective amount of a compound of claim 1, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier. 25. A pharmaceutical composition comprising a therapeutically effective amount of a compound of claim 1, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable diluent. 26. A pharmaceutical composition comprising a therapeutically effective amount of a compound of claim 1, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable adjuvant. 27. The pharmaceutical composition of claim 2, wherein the pharmaceutical composition is administered by intravenous injection, by injection into tissue, intraperitoneally, orally, or nasally. 28. The pharmaceutical composition of claim 2, wherein the pharmaceutical composition has a form selected from the group consisting of a solution, dispersion, suspension, powder, capsule, tablet, pill, time release capsule, time release tablet, and time release pill. 29. The pharmaceutical composition of claim 2, wherein the pharmaceutical composition is a capsule and is administered orally, and wherein the compound is ##STR00034## 30. The pharmaceutical composition of claim 2, wherein the pharmaceutical composition is a tablet and is administered orally, and wherein the compound is ##STR00035## 31. The pharmaceutical composition of claim 2, wherein the pharmaceutical composition is a pill and is administered orally, and wherein the compound is ##STR00036## |
